Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 13/20 | 0.59 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.48 |
| ▸ | FEN1 | P39748 | 4/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | YES1 | P07947 | 3/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | HIPK1 | Q86Z02 | 2/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12372627 | 0.83 | MAPK1 (0.51) | MAPK1RIPK1ALOX5APFEN1 | |
| SCHEMBL12401172 | 0.82 | KIT (0.48) | MAPK1ABL1YES1NTRK1PIM1 | |
| SCHEMBL12400116 | 0.81 | ABL1 (0.43) | MAPK1ABL1YES1NTRK1PIM1 | |
| SCHEMBL12400226 | 0.81 | CAMK2D (0.47) | MAPK1ABL1YES1NTRK1PIM1 | |
| SCHEMBL12372228 | 0.80 | MAPK1 (0.48) | MAPK1RIPK1ALOX5APFEN1 | |
| SCHEMBL12401317 | 0.78 | MAPK1 (0.48) | MAPK1RIPK1ALOX5APFEN1 | |
| SCHEMBL12605504 | 0.76 | MAPK1 (1.00) | MAPK1RIPK1KDR | |
| SCHEMBL28508679 | 0.74 | MAPK1 (0.59) | MAPK1RIPK1 | |
| SCHEMBL14655483 | 0.73 | ATR (0.44) | MAPK1ABL1YES1NTRK1PIM1 | |
| SCHEMBL30208787 | 0.73 | JAK3 (0.63) | MAPK1RIPK1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | MAPK1 386/4885RIPK1 252/4885ALOX5AP 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.